ARCHIVES

Regulatory Approvals: FDA expanded the approved use of Cyramza to include metastatic NSCLC

This article is from The Cancer Letter archive.

Vol. 40 No. 47 | December 19, 2014

Download PDF Visit The Full Archive

Related Articles

More Cost-Effective To Use Cetuximab In Patients With Wild-Type KRAS Gene

August 28, 2009

Henschke Responds To Questions from The New York Times

April 29, 2011

ACS Ask Stronger Federal Action Against Cigarettes

November 23, 1979

Conversation With The Cancer Letter: Hudis: ASCO Vying for Big Role in Big Data

November 22, 2013

FDA To Issue “Complete Response” Letters To Drug Sponsors.

July 11, 2008

caBIG Architect Kenneth Buetow Resigns

December 16, 2011